This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The treatment efficacy of each product was obtained from medical literature. The specific source used to estimate the dose and duration of the treatment was not stated (it might have been the literature, patient chart reviews, or expert opinion).
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
Only data on treatment efficacy were reported.
The range of efficacy used in the model was 0.44 to 0.91 for pFVIII, 0.18 to 0.28 for hFVIII, and 0.49 to 0.80 for APCC.
Methods used to derive estimates of effectiveness
Expert opinions were used in the model to derive estimates of effectiveness.
Estimates of effectiveness and key assumptions
The estimates derived from expert opinions were not reported.
Similarly, if the efficacy of APCC was raised by approximately 15%, initial use of APCC was more effective.
Authors' conclusions
Treatment initiated with porcine factor VIII (pFVIII) would be less costly than treatment sequences initiated with a bypassing agent or human factor VIII (hFVIII). Many physicians believe pFVIII is the preferred strategy based on clinical considerations.
CRD COMMENTARY -Selection of comparators
The reason for the choice of the comparators would appear clear. However, the authors reported in the 'Introduction' section that four therapeutic products were available for acquired haemophilia, but only three were actually compared. No justification for the exclusion of the fourth product (recombinant factor VIIa) was provided. You should decide whether these technologies represent valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The authors reported that published studies were used to estimate the effectiveness. However, they did not report whether a systematic review was conducted. Moreover, the sources searched to identify primary studies, the study designs and other criteria for inclusion in the review, and the validity of the studies were not reported. The authors acknowledged that the base-case scenario was not necessarily generalisable to all patients with an acquired inhibitor.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis. In effect, a cost-consequences analysis was carried out. The reader is therefore referred to the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The perspective of the study was not stated, thus it is not possible to assess whether all the relevant categories of costs were included in the analysis. Discounting was not relevant and was not carried out. Details of the unit costs and price year were reported, which enhance the transferability of the economic analysis to other settings. However, it was unclear how the authors calculated the total costs from the unit cost of each product. It appears that other categories of cost have been used in the cost analysis (e.g. physician services, professional fees, or monitoring), but the authors did not report these. A potentially good feature of the cost analysis was that estimates were varied in the sensitivity analyses. However, the ranges over which costs were varied were not justified. Consequently, the internal and external validity of the cost analysis may be low.
Other issues
The generalisability of the results was hardly addressed. The authors did not compare their findings with those from other studies and did not report any further limitations of their study. The authors reported that a cost-minimisation analysis was conducted, although they reported a general conclusion with regard to both the effectiveness and cost results. The authors used the expression "is preferred", which has no sense in health economics (it was unclear if the strategy was dominant, cost-effective, more effective, less costly). In effect, a cost-consequences analysis was conducted. The authors should also note that an economic analysis of health interventions does not merely refer to monetary evaluations, but also to clinical outcomes.
